Bio-Path Holdings Inc., of Houston, said it completed cohort six of its phase I trial testing Liposomal Grb-2 in blood cancers, showing the compound to be safe and well tolerated, with signs of anti-leukemia activity, and it now plans to move into phase II testing by the end of this year.